natgillin/translations-raw huggingface dataset:
Use according to any one of the preceding claims, characterized in that in the case where the suspension pH prior to AMP addition is between 8.5 and 9, said AMP is added to said suspension in an amount to increase the pH of the suspension by at least 1 pH unit, and that in the case where the suspension pH prior to AMP addition is between 9 and 10, said AMP is added to said suspension in an amount to increase the pH of the suspension by at least 0.7 pH units. 
Uporaba prema bilo kojem od prethodnih zahtjeva, naznačena time da u slučaju gdje je pH suspenzije prije dodavanja AMP između 8.5 1 9, navedeni AMP se dodaje u navedenu suspenziju u količini za povećavanje pH suspenzije za najmanje 1 pH jedinicu, te da u slučaju gdje je pH suspenzije prije dodavanja AMP između 9 1 10, navedeni AMP se dodaje u navedenu suspenziju u količini za povećavanje pH suspenzije za najmanje 0.7 pH jedinica,
A method of treating lymphoma in a patient, comprising administering a therapeutically effective amount of a compound, which is 3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof, wherein the treating refers to ameliorating or inhibiting lymphoma in the patient. 
Farmaceutski sastav koji sadrži spoj koji je 3-ciklopentil-3-[4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propannitril; ili njegovu farmaceutski prihvatljivu sol; i farmaceutski prihvatljiv nosač; pri čemu je navedeni sastav pogodan za oralnu primjenu i za osiguravanje produženog oslobađanja navedenog spoja ili navedene soli.
The compound according to claims 1-12 wherein R8 is the sulfonyl group with R1, and wherein R10 is methyl, and the remaining R6, R7 and R9 are H. 
Spoj prema zahtjevima 1-12, naznačen time što Rg je sulfonil skupina s Ri, i pri čemu Ryg je metil, i preostali Ry,
A fusion peptide according to claim 5 or 6, wherein component (III) comprises at least 10, more preferably at least 20 additional amino acid residues of the N-terminal sequence of GLP-2 as in proglucagon or of GLP-1(7-37). 
Fuzijski peptid prema patentnom zahtjevu 9 ili 10, naznačen time da komponenta (III) obuhvaća najmanje 4, poželjno najmanje 10, a još poželjnije najmanje 20 aminokiselinskih ostataka N-terminalne sekvence od GLP-2 kao u proglukagonu ili od GLP-1(7-37). t>&
DESCRIPTION OF EMBODIMENTS OF THE INVENTION FIG. 
Datum objave europskog patenta:
scanning the irradiated patient-specific three-dimensional model to provide at least one irradiated readout image representing a radiation dose distribution within the irradiated patient-specific three-dimensional model, wherein the at least one irradiated readout image is a three-dimensional image. The method of claim 1, further comprising fusion-registration of (a) the at least one irradiated readout image with, (b) the at least one control readout image. 
skeniranje ozračenog trodimenzionalnog modela specifičnog za pacijenta koji sadrži dozimetar kako bi se osigurala barem jedna slika za očitavanje koja predstavlja raspodjelu doze zračenja unutar pacijentovog trodimenzionalnog modela specifičnog za pacijenta; i kreiranje fuzije-registracije (a) najmanje jedne slike za očitavanje koja predstavlja raspodjelu doze zračenja unutar trodimenzionalnog modela specifičnog za pacijenta sa (b) najmanje jednim skupom prvih medicinskih slika najmanje jednog djela tijela pacijenta.
The larger the pressure needed, the higher the requirements to the pressurizing source, and the higher become the costs of the pressurizing source. 
Å to je potreban veći pritisak, veći su zahtjevi za tlačni izvor, i troškovi za izvor pritiska postaju veći.
3, of a variant of the invention. 
Datum podnošenja europske prijave patenta:
adding to the aqueous preparation one or more aldehyde-releasing biocides and/or biocides with one or more aldehyde groups in an amount such that the total amount of aldehyde-releasing and/or aldehyde-based biocides in the aqueous preparation is from 250 ppm to 5000 ppm, calculated relative to the water in the preparation; 
(a) jedan ili više biocida koji oslobađaju aldehid i/ili biocidi s jednom ili više aldehidnih skupina u količini tako da je ukupna količina biocida koji oslobađaju aldehid i/ili biocida s jednom ili više aldehidnih skupina u vodenom pripravku od 250 ppm do 5000 ppm, izračunato u odnosu na težinu vode u pripravku, te
The method of manufacturing crystalline Form I may include a method where, in step (1) the initial state of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride in an aqueous organic solvent is a solution, and the solution is stirred within the temperature-water activity range I with decreasing the temperature and/ or water activity thereof. 
Metoda za pripravu kristalnog oblika II iz patentnog zahtjeva 2, metoda obuhvaća: a) = grijanje 5-15% masenog udjela (R)-7-kloro-N-(kinuklidin-3-il)benzo[b]tiofen-2-karboksamid hidroklorida u 2-butanolu ili vodenom 2-butanolu između 60"C 1 točke vrenja otopine; b) ako je volumni udio vode manji od 5%, dodavanje vode u smjesu tako da volumni udio vode nije manji od
The mouse of claim 1, wherein the endogenous mouse k immunoglobulin light chain locus comprises a plurality of unrearranged human λ immunoglobulin light chain variable (hVλ) gene segments. 
Miš prema zahtjevu 1, naznačen time, što se alel endogenog lakog 2 (lambda) lanca sastoji od više humanih segmenata gena VA.
may be H, R7, or substituted or unsubstituted aryl or heteroaryl; 
R, je H, R,, ili supstituirani ili nesupstituirani aril ili heteroaril;
The dryer of claim 8 further comprising a feed sensor end switch (116) attached to the second end portion of the feed conveyor housing for detecting when a predetermined quantity of the material has accumulated at the upper end of the conveying means between the first and second endless belts (52, 54). 
Sušilica prema patentnom zahtjevu 8 još obuhvaća 1 krajnji prekidač (116) senzora dovoda postavljen na drugi dio kraja kućišta dovodnog transportera za detektiranje kada je prethodno utvrđena kvaliteta materijala akumulirana na gornjem kraju sredstva za transportiranje između prve i druge beskonačne trake (52, 54).
The pharmaceutical composition of claim 6, wherein the cardiac disorders and diseases are selected from the group consisting of irregular heartbeat disorders and diseases; exercise-induced irregular heartbeat disorders and diseases; sudden cardiac death; exercise-induced sudden cardiac death; congestive heart failure; chronic obstructive pulmonary disease; and high blood pressure, preferably wherein the irregular heartbeat disorders and diseases and exercise-induced irregular heartbeat disorders and diseases are selected from the group consisting of atrial and ventricular arrhythmia; atrial and ventricular fibrillation; atrial and ventricular tachyarrhythmia; atrial and ventricular tachycardia; catecholaminergic polymorphic ventricular tachycardia (CPVT); and exercise-induced variants thereof 
Farmaceutska kompozicija prema patentnom zahtjevu 6, naznačena time što su poremećaji 1 bolesti srca izabrani iz grupe koju čine poremećaji i bolesti nepravilnih srčanih otkucaja; poremećaji 1 bolesti nepravilnih srčanih otkucaja inducirani pojačanom fizičkom aktivnošću; iznenadna srčana smrt; iznenadna srčana smrt inducirana pojačanom fizičkom aktivnošću; kongestivna srčana insuficijencija; kronična opstruktivna bolest pluća; 1 visok krvni tlak, poželjno gdje su poremećaji i bolesti nepravilnih srčanih otkucaja i poremećaji i bolesti nepravilnih srčanih otkucaja inducirani pojačanom fizičkom aktivnošću izabrani iz grupe koju čine atrijalna i ventrikularna aritmija; atrijalna i ventrikularna fibrilacija; oatrijalna 1 = ventrikularna tahiaritmija; atrijalna 1 = ventrikularna tahikardija; katekolaminergična polimorfna ventrikularna tahikardija (CPVT); 1 njihove varijante inducirane pojačanom fizičkom aktivnošću.
The method of claim 1, wherein the frozen G-CSF composition in step (c) is stored over a period of at least two days. 
Postupak prema bilo kojem zahtjevu od 1 do 7, naznačen time, da se zamrznuti G-CSF-sastav u koraku (c) pohranjuje u vremenskom periodu od najmanje tri mjeseca.
The device according to one of claims 1 to 9 wherein the variable gap is a largest gap which is an integer multiple of the RBG size and which is available based on the system bandwidth. 
Integrirani krug sukladno jednom od zahtjeva 1 do 14, naznačen time da je razmak najveći od razmaka koji su cjelobrojni višekratnici broja uzastopnih PRB-ova koji tvore RBG 1 koji su dostupni ovisno o propusnosti sustava.
Compound of any one of claims 1 to 7 for use in the treatment, prevention or amelioration of pain, wherein the pain is selected from the group consisting of chronic pain, neuropathic pain, inflammatory pain, pain due to osteoarthritis, pain due to arthritis, pain due to rheumatoid arthritis, cancer pain, pain due to spinal cord injury, surgical pain, post-operative pain or acute pain. 
i njegove farmaceutski prihvatljive soli i solvati. Spoj za uporabu prema zahtjevu 15, naznačen time da je bol odabrana iz skupine koja sadrži kroničnu bol, neuropatsku bol, upalnu bol, bol zbog osteoartritisa, bol zbog artritisa, bol zbog reumatoidnog artritisa, bol zbog karcinoma, bol zbog ozljede leđne moždine, operativnu bol, postoperativnu bol ili akutnu bol.
On day 14 post-implant, mice were randomised into groups of 10 prior to the treatment with compound or vehicle control that was administered once daily at 0.1ml/kg body weight. 
Prije tretmana sa spojem ili nosačem kao kontrolom koij su im davani jednom dnevno u dozi od 0.1 ml/kg tjelesne težine, miševi su nasumično raspoređeni u grupe od 10 miševa.
Further disclosed herein is a process for making a compound of formula (II), comprising the following step: wherein X, Y, Ra, PG1 and PG2 are as defined above. 
R* je hidroksi R, je Cr4 alkil ili aril. 2. | Postupak za pripremu spoja formule (II), koji sadrži sljedeći korak: ePEa d
o a first operative condition (I) representing an ordinary functioning of said machine (1), wherein said operator (7) is electrically isolated from said machine (1); 
- < prvom operativnom stanju (I) koje predstavlja uobičajeno funkcioniranje navedenog stroja (1), gdje je navedeni operater (7) strujno izoliran od navedenog stroja (1);
assigning a solid solution whose drug loading is below the upper concentration limit as likely stable against crystallization 
Cc) određivanje čvrste otopine čiji je sastav lijeka ispod gornje granice koncentracije kao vjerojatno stabilne na kristalizaciju.
The isolated fusion protein of any one of claims 5-9, wherein the biologically active protein has at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or 100% sequence identity to a coagulation factor selected from the group consisting of factor IX (SEQ ID NOS:1735-1746), factor VIIa, or factor VII (SEQ ID NO:1747). 
Izolirani fuzijski protein prema jednom od zahtjeva 5 do 9, naznačen time, da biološki aktivan protein ima najmanje 95%, ili najmanje 96%, ili najmanje 97%, ili najmanje 98%, ili najmanje 99% ili 100% identiteta sekvence prema faktoru koagulacije odabranom iz skupine koja se sastoji od faktora IX (SEQ ID NO: 1735-1746), faktora VIlIa, ili faktora VII (SEQ ID NO: 1747).
A process according to claim 7 comprising: the in situ generation of the imine 4 from the aldehyde (R1CHO) and an amine (R2NH2, preferably PhCH2NH2, in acetonitrile at room temperature and in presence of molecular sieves or by distillation of the azeotropic mixture acetonitrile/water; 
Postupak prema patentnom zahtjevu 7, naznačen time da obuhvaća – in situ generiranje imina 4 iz aldehida (R1CHO) i amina (R2NH2, preferirano PhCH2NH2) u acetonitrilu pri sobnoj temeraturi u prisutnosti molekulskih sita ili destilacijom azeotropne smjese acetilnitril/vode;
Lubricants include magnesium stearate, calcium stearate, glyceryl monostearate, glyceryl palmitostearate, hydrogenated castor oil, hydrogenated vegetable oil, mineral oil, polyethylene glycol, sodium benzoate, sodium lauryl sulfate, sodium stearyl fumarate, stearic acid, talc and zinc stearate. 
Lubrikanti uključuju magnezijev stearat, kalcijev stearat, gliceril monostearat, gliceril palmitostearat, hidrogenirano ricinusovo ulje, hidrogenirano biljno ulje, mineralno ulje, polietilen glikol, natrijev benzoat, natrijev lauril sulfat, natrijev stearil fumarat, stearinske kiseline, talk i cinkov stearat.
A method according to Claim 3, wherein the sheet-form material is heated to a temperature greater than about 100 degrees C, preferably greater than 120 degrees C. 
Postupak prema zahtjevu 1, naznačen time, da se pločasti materijal za oblikovanje zagrijava na temperaturu višu od oko 120 stupnjeva C.
In one aspect, the disclosure features a composition that includes a protein having a free thiol and a carbohydrate, wherein the carbohydrate is present in an amount sufficient to maintain the stability of the protein and wherein the pH of the composition is less than 7.0. 
Farmaceutska kompozicija koja sadrži protein koji ima slobodni tiol i ugljikohidrat, pri čemu je ugljikohidrat prisutan u količini koja je dovoljna za održavanje stabilnosti proteina i pri čemu je pH kompozicije između 4,5 1 6,5, pri čemu je protein koji ima slobodni tiol glukocerebrozidaza (GCB) i pri čemu je ugljikohidrat saharoza.
The arrester according to claim 14, characterized in that the insulating body includes a hollow component, wherein the additional electrode is placed inside the hollow component. 
Gromobran u skladu s patentnim zahtjevom 14, naznačen time što izolirajuće tijelo (1) uključuje šuplju komponentu, gdje se dodatna elektroda (7) nalazi unutar šuplje komponente.
the second domain VHB and the third domain VLB is specific for a tumor cell; 
- < druga domena VEB i treća domena VLB su specifične za tumorsku stanicu;
A process for preparing a crystalline form (Form C) of N-(3-cyano-4-methyl-1 H -indol-7-yl)-3-cyanobenzenesulfonamide according to any one of claims 1 to 6, characterized in that a crystalline form of N-(3-cyano-4-methyl-1 H -indol-7-yl)-3-cyanobenzenesulfonamide hydrate are heated at 80-130°C. 
Postupak za pripravu kristalnog oblika (Oblik C) spoja N-(3-cijano-4-metil-1H-indol-7-il)-3-cijanobenzen-sulfonamida u skladu s bilo kojim patentnim zahtjevom 1 do 6, naznačen time, da se kristalni oblik spoja N-(3-cijano-4-metil-1H-indol-7-il)-3-cijanobenzen-sulfonamid hidrata zagrijava na 80-130°C.
each R3 is independently H, —CN, —CF3, or —CH3; and is optionally substituted morpholinyl or optionally substituted piperazinyl. 
svaki R3 je neovisno H, -CH3 ili -CF3; i je izborno supstituirani morfolinil, izborno supstituirani piperazinil ili izborno supstituirani piperidinil.
with an amine or where A and X are NH, it comprises the step of condensing an organomettalic reagent ArM onto a compound of formula (VI): 
B, ili - kada A 1 X predstavljaju NH, postupak sadrži korak kondenziranja organometalnog reagensa ArM na spoju formule (VI): posaoaa,
The homogenate is centrifuged at 600×g for 10 min at 4° C. The pellet is discarded and the supernatant is centrifuged at 20.000×g for 55 min. 
Homogenat se centrifiigira kod 600x g tijekom 10 min., na 4 stupnjeva C. Pelet se uklanja a supernatant se centrifugira na 20.000 x g tijekom 55 minuta.
A method for screening of a pharmaceutically active compound for the treatment and/or the prevention of fibrosis and/or fibrosis related diseases or a predisposition thereof, comprising the steps of: 
In vitro postupak za provjeravanje farmaceutski aktivnog spoja za liječenje i/ili sprečavanje fibroze ili za njenu predispoziciju, naznačen time da sadrži slijedeće korake davanje uzorka koji sadrži miR-21;
preparing a compound of formula 26 via arylation of the prepared compound of formula 27 with a compound of formula R1-H followed by halogenation; 
pripravu spoja s formulom 26 putem arilacije pripremljenog spoja s formulom 27 sa spojem s formulom R1-H nakon čega slijedi halogeniranje;
In certain embodiments, the present invention relates to a dosage form of the medicament wherein the GPR119 agonist and the DPP-IV inhibitor are in amounts sufficient to lower a blood glucose level in a subject. 
Pripravak u skladu sa zahtjevom 32, naznačen time, da GPR119 agonist i DPP-IV inhibitor su u količinama dovoljnim da snize nivo glukoze u krvi kod subjekta.
The method of claim 10, wherein the at least two low affinity human FcYR genes further comprise a gene encoding a human FcYR a-subunit selected from an FcYRIIA a-subunit, FcYRIIB a-subunit, an FcYRIIC a-subunit, an FcYRIIIB a-subunit, and a combination thereof. 
Način prema zahtjevu 10, naznačen time, što najmanje dva humana gena FcyR s niskim afinitetom dodatno sadrže humanu FcyR o-podjedinicu koja kodira gene odabranu iz FcyRIIA o-podjedinice, FcyRIIB a-podjedinice, FcyRIIC a-podjedinice, FcyRIIIB a-podjedinice ili njihove kombinacije.
The method according to claim 23, wherein said sealing area is provided with sealing tapes or extensions of the lower edge of the upper, obtained by elements which are fixed to said upper by sewing or adhesive bonding. 
Postupak u skladu s jednim ili više od prethodnih patentnih zahtjeva, naznačen time, da se navedeni vodonepropusni spoj (26) ostvaruje brtvenim vrpcama ili produžecima (28) donjeg ruba gornjišta dobivenih pomoću elemenata koji se na navedeno gornjište pričvršćuju šivanjem, lijepljenjem ili sličnim postupkom.
Advantageously, adjuvants such as a local anaesthetic, preservatives and buffering agents are dissolved in the vehicle. 
Adjuvansi, poput lokalnih anestetika, konzervansa i puferskih sredstava se pogodno otapaju u vehikulumu.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidenebenzonorbornene-5-yl)amide and as component (B) bixafen. 
Pripravak prema zahtjevu 1, naznačen time da je komponenta (A) 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-iljamid i komponenta (B) je odabrana od azoksistrobina i pikoksistrobina.
wherein a substituted aryl or heteroaryl group can be substituted by one or more substituents selected from the group consisting of halogen, hydroxyl, alkoxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, carboxylate, alkylcarbonyl, cyano, amino, acylamino, sulfhydryl, alkylthio, arylthio, nitro, trifluoromethyl and cyano; and wherein a substituted alkyl may be substituted by one or more substituents selected from the group consisting of alkenyl, alkoxy, alkoxycarbonyl, alkoxycarbonyloxy; alkynyl, alkylcarbonyl, alkylthio, alkythiocarbonyl, thiocarboxylate, arylthio, arylcarbonyl, arylcarbonyloxy, acylamino, carboxylate, cyano, halogen, haloalkyl, cycloalkoxy, acetamide, amine, hydroxyl, nitro, sulfhydryl, sulfonamido and trifluoromethyl; 
gdje supstituirana aril ili heteroaril skupina može biti supstituirana s jednim ili više supstituenata odabranih iz skupine koja se sastoji od halogena, hidroksila, alkoksila, alkilkarboniloksija, arilkarboniloksija, alkoksikarboniloksija, karboksilata, alkilkarbonila, cijano, amino, acilamino, sulfhidrila, alkiltio, nitro, trifluorometila i cijano; i gdje supstituirani alkil može biti supstituiran s jednim ili više supstituenata odabranih iz skupine koja se sastoji od alkenila, alkoksija, alkoksikarbonila, alkoksikarboniloksija; alkinila, alkilkarbonila, alkiltio, alkiltiokarbonila, tiokarboksimida, amina, hidroksila, nitro, sulfhidrila, sulfonamida i trifluorometila;
The method of claim 1, wherein the indication of the resource set is an absolute indication. 
Metoda iz bilo kojeg od prethodnih patentnih zahtjeva, gdje je indikacija skupa resursa apsolutna indikacija.
and A2 each independently mean a nitrogen atom, or mean a methine group optionally substituted with a halogen atom, a hydroxyl group, a cyano group, a C1-C6 alkyl group, a C1-C6 alkoxy group or a hydroxy-C1-C6 alkyl group; 
i A2 svaki nezavisno predstavlja atom dušika, ili predstavlja metinsku grupu opcionalno supstituiranu s atomom halogena, hidroksilnu grupu, cijano grupu, C1-C6 alkilnu grupu, C1-C6 alkoksi grupu ili hidroksi- C1-C6 alkilnu grupu;
The components are in diagrammatic form for illustration and are not to scale. 
Komponente su prikazane shematski i nisu u razmjeru.
(2003)); the inhibitory effect on tissue damaging enzymes (matrix metalloproteinases, particularly the MMP-9) which are produced in increased amount by invasive cells, while the sodium-HA salt does not show the latter effect (WO 00/53194, Illés et al.1999). 
(2003)); inhibitorni učinak na enzime koji uništavaju tkivo (metaloproteinaze matriksa, posebno MMP-9) koji se proizvode u povećanoj količini sa invazivnim stanicama, dok natrij-HA sol ne pokazuje kasniji učinak (WO 00/53194, Ill6s et al. 1999).
reacting the capsular saccharide with [(R3C(O)]2O in the presence of an imidazole catalyst. 
(bljreakcije saharida kapsule s [(R*C(O)bO, u prisutnosti imidazola kao katalizatora.
X is a carboxylic acid or a derivative thereof wherein the derivative is a carboxylic ester, a carboxamide, a monoglyceride, a diglyceride, a triglyceride, or a phospholipid; 
X je karboksilna kiselina ili njen derivat pri čemu je derivat karboksilni ester, karboksamid, monoglicerid, diglicerid, triglicerid ili fosfolipid; ili njegova farmaceutski prihvatljiva sol.
This embodiment can be represented by Formula (IIa) as illustrated below: wherein each variable in Formula (IIa) has the same meaning as described herein, supra and infra, and Z is -O- -S-, -S(O)-, or -S(O)2-. 
Taj oblik se može prikazati Formulom (Ifa) prikazanom dolje: gdje svaka gdje svaka varijabla u Formuli (IIa) ima isto značenje kao što je opisano u tekstu, supra i infra, te Z je-O-, - S-, ili -5(O),-.
A preparation selected from an LIF preparation or an LIF mimetic for use in a method of treating GBM by decreasing the number of tumor stem cells and/or tumor progenitor cells in a GBM tumor. 
Farmaceutski pripravak, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što terapijska količina smanjuje vjerojatnost pojave simetrične diobe kod tumorske matične stanice ili stanice preteče tumora.
W represents —OP2, in which P2 represents hydrogen or a protecting group. 
W predstavlja POP", gdje P* predstavlja vodik ili zaštitnu grupu. sa spojem formule (4);
The compounds of this invention are also useful as an adjunct to treatment of growth hormone deficiency and short stature, and for the treatment of systemic lupus erythematosis. 
Spojevi prema ovom izumu također su korisni kao pomoćna terapija manjka hormona rasta i niskog rasta, te za liječenje sistemičnog eritematoznog lupusa.
coupling said compound of formula (V) with a compound of formula (VI): 
(11) kondenzacija spoja formule (V) sa spojem formule (VI) "GH č
Another embodiment is directed to the crystalline sodium salt of Compound (1) exhibiting an XRPD pattern substantially the same as that shown in FIG. 3 . 
Kristalna natrijeva sol prema zahtjevu 2, naznačena time, da ima uzorak difrakcije praha X-zraka izmjeren uporabom radijacije CuKa, koji je uglavnom isti kao onaj prikazan na Slici 3.
The filters disposed in the filter holders can, as already stated, be of the single or multilayer filter mesh type. 
Filtri koji su stavljeni u držače za filtre mogu, kao što je to već navedeno, biti filtri takve vrste koji imaju jednostruku ili višeslojnu mrežu.
The poxvirus according to claim 6 wherein said protein having at least a cytosine deaminase activity is the FCU1-8 polypeptide represented in the sequence identifier SEQ ID N°:2 and analogues thereof. 
Poksvirus u skladu s patentnim zahtjevom 6, naznačen time što navedeni protein koji u najmanju ruku ima aktivnost citozinske deaminaze je FCU1-8 polipeptid prikazan u identifikatoru slijeda SEQ ID NO:2 i njegovim analozima.
The system according to any of claims 1 to 3, characterised in that said first separation means (4) for separating the light fraction comprise at least one of a comb conveyor (16) and a suction system (5). 
Sustav prema bilo kojem od zahtjeva 1 do 3, naznačen time što prva separacijska sredstva (4) za razdvajanje lagane frakcije obuhvaćaju barem jedno između pokretne trake u izvedbi češlja (16) 1 usisnog sustava (5).